NCT01774071 (Clinical Trial / Vandortuzumab Vedotin (DSTP3086S / RG7450 / MSTP2109A)

Study Title
Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer (NCT01774071)

Trial Description
The purpose of this study is to see if a new diagnostic research agent named 89Zr-DFO-MSTP2109A can show prostate cancer tumors on a PET scan; as well as see how long 89Zr-DFO-MSTP2109A lasts in the blood when given in small amounts.

DFO-MSTP2109A is an antibody that works against Six Transmembrane Epithelial Antigen of the Prostate 1 (PRSS24) or STEAP1 – found on the surface of prostate cancer cells. Attached to the DFO-MSTP2109A is a radioactive material called 89ZR, which allows it to be imaged by a PET scanner.

The results of this study may help researchers know whether 89Zr-DFO-MSTP2109A can be used as a diagnostic agent for finding prostate cancer that have STEAP1 on its surface with a PET scanner. The reason why identifying STEAP1 on prostate cancer cells is that new therapies are being developed to target STEAP1 prostate cancer cells.


This trial is sponsored by Memorial Sloan Kettering Cancer Center. [1]

Study Data

  • Condition: Prostate Cancer
  • Interventions:
    • Drugs used in this trial
      • 89Zr- DFO-MSTP2109A (Also known as DSTP-3086S, DSTP3086S, MSTP2109A, RG-7450, RG7450)
  • Phase: I & II
  • Estimated Enrollment: 27
  • Start: January 2013
  • Estimated Completion: January 2016
  • Last verified: May 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 14, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.